IRLAB Therapeutics has announced that its CEO Richard Godfrey is leaving his position and that the Board of directors has appointed Gunnar Olsson as Interim CEO.
This news follows the disappointing Phase IIb trial results of mesdopetam in people with Parkinson's disease levodopa-induced dyskinesi